She Was “Too Healthy” for Breast Cancer—She Proved Them Wrong
- Despite being told she was “too healthy” for breast cancer, four-time Olympian Chaunte Lowe, 34, trusted her instincts and sought a second opinion about a concerning lump in her breast—leading to an early diagnosis of triple-negative breast cancer.
- Lowe’s treatment included a double mastectomy (removal of both breasts) and six rounds of chemotherapy. Some patients may find immunotherapy helpful, which involves using the patient’s reengineered immune cells to fight the cancer.
- Triple-negative breast cancer is an aggressive form of the disease, but it often responds well to chemotherapy as opposed to targeted therapy like hormone therapy because this type of breast cancer is not fueled by any of the three main types of receptors: estrogen, progesterone, or the HER2 protein. Typically, chemo is the first line of treatment; however, more recently, immunotherapy has emerged as an option for some triple-negative breast cancer patients.
- According to Dr. Heather McArthur, previously medical director of breast oncology at Cedars-Sinai Medical Center, studies suggest that giving patients immunotherapy early on in the treatment of metastatic triple-negative breast cancer works better than when taken after chemotherapy.
- SurvivorNet experts say treating triple-negative breast cancer may involve chemo before surgery (neoadjuvant chemotherapy) to shrink the tumor, making it easier to surgically operate on. Neoadjuvant chemo can also tell doctors if you’ll need additional treatment after surgery. Some patients with triple-negative breast cancer may also need radiation after surgery.
- A research team at Mayo Clinic identified a group of genes linked to an increased risk of developing triple-negative breast cancer, aiding with earlier detection. BARD1, BRCA1, BRCA2, PALB2, and RAD51D were genes associated with a higher risk of triple-negative breast cancer.
The lump turned out to be triple-negative breast cancer, one of the most aggressive forms of the disease.

“That misdiagnosis could have meant that I wasn’t there for my kids,” Lowe shared on the “Health is Wealth” show.
A Georgia Tech graduate with a degree in economics, Lowe competed in the 2004, 2008, 2012, and 2016 Olympic Games, earning bronze, silver, and gold medals according to her speaker’s biography. But in 2019, she added a new title to her resume: cancer survivor.
“I was fit. I had my three children. I nursed them for 12 months—even while training. I felt great about my health,” Lowe recalled. But her perspective shifted when fellow Olympian Novlene Williams-Mills was diagnosed with breast cancer just weeks before the 2012 Games. Williams-Mills taught Lowe how to perform a self-breast exam—on a moving bus in Paris, no less.
Regular self-breast exams can help women become more familiar with how their breasts normally look and feel—making it easier to notice any changes, like a new lump or unusual texture.
WATCH: Getting to know your breasts with self-breast exams.
“For some women, especially those with fibrocystic breasts, it can be tricky to tell what’s normal,” explains medical oncologist Dr. Elizabeth Comen. “Their breasts may naturally feel lumpy or bumpy, which is why consistency and awareness are so important.”
Dr. Comen recommends doing a self-exam about once a month—but not right before your period, when breasts can be more swollen or tender. “Many women find it easiest to do in the shower, when the skin is wet and slick,” she adds. “And if you feel something unusual—like a lump in your breast or even in your armpit—it’s important to bring it to your doctor’s attention.”
That moment stuck with Lowe. Years later, it led her to detect the rice-sized lump that doctors initially dismissed as a swollen lymph node.
“They told me not to come back for six years,” she said. But when she returned for a second opinion, the lump had tripled in size.
“If I had any advice for you following a cancer diagnosis, it would be, first, to seek out multiple opinions as to the best care,” National Cancer Institute chief of surgery, Dr. Steven Rosenberg, tells SurvivorNet. “Finding a doctor who is up on the latest information is important, and it’s always important to get other opinions so that you can make the best decisions for yourself in consultation with your care providers.”
WATCH: The Difference a Second Opinion Can Make.
Triple-negative breast cancer doesn’t respond to hormone therapy or HER2-targeted treatments, making chemotherapy the primary option.
“We classify triple-negative breast cancers as one of the most aggressive types,” said Dr. Irene Wapnir, a breast surgeon at Stanford Medicine.
Lowe underwent a double mastectomy (removal of both breasts) and six rounds of chemotherapy.
“Making the decision to do the full mastectomy instead of the lumpectomy was an easy one,” she shared on Instagram. “I have a lifetime of monitoring ahead.”
View this post on Instagram
“Due to the very aggressive nature of this type of breast cancer, I would need to complete six rounds of chemotherapy, possibly radiation, and I have a lifetime of monitoring,” Lowe explained to Susan G. Komen, one of the leading breast cancer advocacy and research foundations.
WATCH: Treating Triple-Negative Breast Cancer
Despite the physical toll, Lowe found strength in her athletic mindset.
“After the initial shock, thinking I was going to die, I found hope. I tapped into what made me strong as an athlete,” she said.

Her doctor encouraged her to keep training, reminding her that having something to look forward to could be healing.
Today, Lowe uses her platform to advocate for early detection and self-awareness. “Even six months can make a huge difference,” she posted. “Feel your boobs, ladies!
Expert Resources on Triple-Negative Breast Cancer
- ‘It’s A Game Changer’: FDA Approves Keytruda, Chemo Combo To Treat Aggressive Triple-Negative Breast Cancer
- A New Treatment Combination Shows Promise For Hard-To-Treat Triple-Negative Breast Cancer — What New Data Means For Patients
- Chemo Plus Immunotherapy for Metastatic Triple-Negative Breast Cancer
- How to Treat Triple-Negative Breast Cancer: Keytruda Shows Promising Boost in Survival
- Metastatic Triple-Negative Breast Cancer Treatments To Consider
- New Study Identifies Genes Linked to Increased Risk for Triple-Negative Breast Cancer
- Treatment for Early Stage Triple-Negative Breast Cancer
Treating Triple-Negative Breast Cancer
SurvivorNet experts say that triple-negative breast cancer often responds well to chemotherapy. Early stages of this disease (stages 1, 2, or 3) mean that the cancer is confined to the breast and/or lymph nodes that are located right under the arm.
“Our primary line of attack is chemotherapy, and this is regardless of the cancer stage,” Dr. Comen said.
Chemotherapy before you have surgery, also called neoadjuvant therapy, has the primary goal of trying to shrink the tumor before the primary treatment is given, which, in the case of breast cancer, is usually surgery.
WATCH: Undergoing Chemo During Triple-Negative Breast Cancer Treatment
In some cases, doctors may recommend chemotherapy after surgery, also known as adjuvant therapy. This additional treatment may be necessary if there are still cancer cells present, or it might be given to lower the risk that the cancer will come back.
There are different chemotherapy options depending on the burden of disease, which refers to how sick someone is with their disease.
“If the disease burden is not too great, meaning that a woman doesn’t have a lot of symptoms, we can often start with oral chemotherapy,” Dr. Comen explains to SurvivorNet.
“After three months of treatment, we can say, how has the response been, has the disease burden decreased, which is what we hope to see, and ideally, we will continue on that treatment for as long as possible. At some point, a woman may become resistant to the treatment that she’s on, which often means IV chemotherapy is next in line.”
The IV chemotherapy cycle can be two weeks on, one week off, alongside monthly doctor visits.
According to Dr. Heather McArthur, previously medical director of breast oncology at Cedars-Sinai Medical Center, studies suggest that giving these drugs early on in the treatment of metastatic triple-negative breast cancer works better than when taken after chemotherapy.
WATCH: Immunotherapy and Triple Negative Breast Cancer
Clinical trials also suggest that for women with non-metastatic triple-negative breast cancer who received immunotherapy and chemotherapy before surgery, 80 percent of these women had a “pathologically complete response” at the time of surgery, meaning there were no cancer cells left in the breast. These trials led to the approval of Keytruda (pembrolizumab) for the treatment of early-stage triple-negative breast cancer. Keytruda can be used with chemotherapy before surgery and then continued alone after surgery if you are at high risk for your breast cancer returning.
RELATED: Triple-Negative Breast Cancer More Deadly Among Black Women
Genetic Testing to Gauge Triple-Negative Breast Cancer Risk
A research team at Mayo Clinic has identified a group of genes linked to an increased risk of developing triple-negative breast cancer (TNBC)—a discovery that could pave the way for improved screening and earlier detection of this aggressive disease.
“Everybody is nervous about triple-negative breast cancer,” says Dr. Marleen Meyers, a medical oncologist at NYU Perlmutter Cancer Center. “Of all the breast cancers, it’s considered the most aggressive and the most difficult to treat.”
WATCH: Genetic Tests for Triple-Negative Breast Cancer Risk
In the 2018 study involving more than 10,000 people diagnosed with TNBC, researchers found that mutations in five genes—BARD1, BRCA1, BRCA2, PALB2, and RAD51D—were associated with a significantly higher risk of developing the disease. Among Caucasian participants, these mutations also correlated with a greater than 20% lifetime risk for breast cancer overall. Similar patterns were observed in African-American participants.
While this genetic insight is promising, experts caution that only about 10% of breast cancers are hereditary. “Most women who undergo genetic testing won’t test positive for these mutations,” explains Dr. Ophira Ginsburg, Director of the High-Risk Cancer Program at NYU Langone’s Perlmutter Cancer Center.
WATCH: When to Get Genetic Testing?
That’s why genetic testing is typically recommended for women with a strong family history—especially those with relatives who’ve had breast or ovarian cancer, rare cancers, or cancers linked to Lynch Syndrome, a hereditary condition that increases cancer risk. Early identification in these high-risk groups can be critical for prevention and timely treatment.
Breast Cancer Symptoms & Self-Exams
Women are encouraged to do regular self-exams to become familiar with how their breasts feel normally, so when something unusual, like a lump, does form, it can be easily detected. A self-exam includes pressing your fingertips along your breast in a circular motion.
For some women, that means going to their doctor and walking through what a self-breast exam looks like, so they know what normal breast tissue feels like, so if they do feel something abnormal, whether it’s a lump or discharge from the nipple, they know what to ask and what to look for.
Below are common symptoms to look out for:
- New lump in the breast or underarm (armpit)
- Any change in the size or shape of the breast
- Swelling of all or part of the breast
- Skin dimpling or peeling
- Breast or nipple pain
- Nipple turning inward
- Redness or scaliness of the breast or nipple skin
- Nipple discharge (not associated with breastfeeding
When to Screen for Breast Cancer
The medical community has a broad consensus that women should have annual mammograms between the ages of 45 and 54. However, an independent panel of experts called the U.S. Preventive Services Task Force (USPSTF) is saying that women should now start getting mammograms every other year at the age of 40, suggesting that this lowered age for breast cancer screening could save 19% more lives.
The American Cancer Society recommends getting a mammogram every other year for women 55 and older. However, women in this age group who want added reassurance can still get annual mammograms.
WATCH: When you’re getting a mammogram, ask about dense breasts.
Women with a strong family history of breast cancer, a genetic mutation known to increase the risk of breast cancer, such as a BRCA gene mutation, or a medical history, including chest radiation therapy before the age of 30, are considered at higher risk for breast cancer.
Experiencing menstruation at an early age (before 12) or having dense breasts can also put you into a high-risk category. If you are at a higher risk of developing breast cancer, you should begin screening earlier.
Questions For Your Doctor
- What stage is my cancer, and how does that affect my treatment plan?
- What are the recommended chemotherapy options for triple-negative breast cancer, and what side effects should I expect?
- Are there any clinical trials or emerging treatments I should consider?
- How will treatment affect my fertility, physical activity, or ability to work?
- What follow-up care and monitoring will I need after treatment ends?
Learn more about SurvivorNet's rigorous medical review process.
